85 related articles for article (PubMed ID: 9102215)
1. Tamoxifen causes gene mutations in the livers of lambda/lacI transgenic rats.
Davies R; Oreffo VI; Martin EA; Festing MF; White IN; Smith LL; Styles JA
Cancer Res; 1997 Apr; 57(7):1288-93. PubMed ID: 9102215
[TBL] [Abstract][Full Text] [Related]
2. 1,3-butadiene: cancer, mutations, and adducts. Part II: Roles of two metabolites of 1,3-butadiene in mediating its in vivo genotoxicity.
Recio L; Saranko CJ; Steen AM
Res Rep Health Eff Inst; 2000 Mar; (92):49-87; discussion 141-9. PubMed ID: 10925839
[TBL] [Abstract][Full Text] [Related]
3. Mutational spectra of tamoxifen-induced mutations in the livers of lacI transgenic rats.
Davies R; Oreffo VI; Bayliss S; Dinh PA; Lilley KS; White IN; Smith LL; Styles JA
Environ Mol Mutagen; 1996; 28(4):430-3. PubMed ID: 8991074
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen induces G:C-->T:A mutations in the cII gene in the liver of lambda/lacI transgenic rats but not at 5'-CpG-3' dinucleotide sequences as found in the lacI transgene.
Davies R; Gant TW; Smith LL; Styles JA
Carcinogenesis; 1999 Jul; 20(7):1351-6. PubMed ID: 10383911
[TBL] [Abstract][Full Text] [Related]
5. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
6. 17 Beta-estradiol and not genistein modulates lacI mutant frequency and types of mutation induced in the heart of ovariectomized big blue rats treated with 7, 12-dimethylbenz[a]anthracene.
Manjanatha MG; Shelton SD; Rhodes BS; Bishop ME; Lyn-Cook LE; Aidoo A
Environ Mol Mutagen; 2005; 45(1):70-9. PubMed ID: 15611980
[TBL] [Abstract][Full Text] [Related]
7. No-effect level in the mutagenic activity of the drug cyproterone acetate in rat liver. Part I. Single dose treatment.
Topinka J; Oesterle D; Reimann R; Wolff T
Mutat Res; 2004 Jun; 550(1-2):89-99. PubMed ID: 15135643
[TBL] [Abstract][Full Text] [Related]
8. Analysis of mutations and bone marrow micronuclei in Big Blue rats fed leucomalachite green.
Manjanatha MG; Shelton SD; Bishop M; Shaddock JG; Dobrovolsky VN; Heflich RH; Webb PJ; Blankenship LR; Beland FA; Greenlees KJ; Culp SJ
Mutat Res; 2004 Mar; 547(1-2):5-18. PubMed ID: 15013694
[TBL] [Abstract][Full Text] [Related]
9. NTP Technical Report on the comparative toxicity studies of allyl acetate (CAS No. 591-87-7), allyl alcohol (CAS No. 107-18-6) and acrolein (CAS No. 107-02-8) administered by gavage to F344/N rats and B6C3F1 mice.
Irwin RD
Toxic Rep Ser; 2006 Jul; (48):1-73, A1-H10. PubMed ID: 17160105
[TBL] [Abstract][Full Text] [Related]
10. 1,3-butadiene: cancer, mutations, and adducts. Part III: In vivo mutation of the endogenous hprt genes of mice and rats by 1,3-butadiene and its metabolites.
Walker VE; Meng Q
Res Rep Health Eff Inst; 2000 Mar; (92):89-139; discussion 141-9. PubMed ID: 10925840
[TBL] [Abstract][Full Text] [Related]
11. Tissue-specific mutant frequencies and mutational spectra in cyclophosphamide-treated lacI transgenic mice.
Gorelick NJ; Andrews JL; deBoer JG; Young R; Gibson DP; Walker VE
Environ Mol Mutagen; 1999; 34(2-3):154-66. PubMed ID: 10529740
[TBL] [Abstract][Full Text] [Related]
12. Investigating DNA adduct-targeted mutagenicity of tamoxifen: preferential formation of tamoxifen-DNA adducts in the human p53 gene in SV40 immortalized hepatocytes but not endometrial carcinoma cells.
Besaratinia A; Pfeifer GP
Biochemistry; 2005 Jun; 44(23):8418-27. PubMed ID: 15938631
[TBL] [Abstract][Full Text] [Related]
13. NTP toxicity studies of carisoprodol (CAS No. 78-44-4) administered by Gavage to F344/N rats and B6C3F1 mice.
Chan PC
Toxic Rep Ser; 2000 Aug; (56):1-G14. PubMed ID: 11986679
[TBL] [Abstract][Full Text] [Related]
14. No-effect level in the mutagenic activity of the drug cyproterone acetate in rat liver. Part II. Multiple dose treatment.
Topinka J; Oesterle D; Reimann R; Wolff T
Mutat Res; 2004 Jun; 550(1-2):101-8. PubMed ID: 15135644
[TBL] [Abstract][Full Text] [Related]
15. Organ specificity of DNA adduct formation by tamoxifen and alpha-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment.
Phillips DH; Hewer A; Osborne MR; Cole KJ; Churchill C; Arlt VM
Mutagenesis; 2005 Jul; 20(4):297-303. PubMed ID: 15928012
[TBL] [Abstract][Full Text] [Related]
16. Mutagenic activity of cisplatin in the lacZ plasmid-based transgenic mouse model.
Louro H; Silva MJ; Boavida MG
Environ Mol Mutagen; 2002; 40(4):283-91. PubMed ID: 12489119
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen-DNA adduct formation in rat liver determined by immunoassay and 32P-postlabeling.
Divi RL; Osborne MR; Hewer A; Phillips DH; Poirier MC
Cancer Res; 1999 Oct; 59(19):4829-33. PubMed ID: 10519392
[TBL] [Abstract][Full Text] [Related]
18. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
19. NTP technical report on the toxicity studies of Riddelliine (CAS No. 23246-96-0) Administered by Gavage to F344 Rats and B6C3F1 Mice.
Chan P
Toxic Rep Ser; 1993 Dec; 27():1-D9. PubMed ID: 12209179
[TBL] [Abstract][Full Text] [Related]
20. NTP Toxicology and Carcinogenesis Studies of Oxymetholone (CAS NO. 434-07-1) in F344/N Rats and Toxicology Studies of Oxymetholone in B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Aug; 485():1-233. PubMed ID: 12571678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
